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CMV-independent increase in CD27−CD28+ CD8+ EMRA
T cells is inversely related to mortality in octogenarians
Carmen Martin-Ruiz1,2, Jedrzej Hoffmann3, Evgeniya Shmeleva 4, Thomas von Zglinicki1,5, Gavin Richardson 1, Lilia Draganova 6,
Rachael Redgrave1, Joanna Collerton1, Helen Arthur1, Bernard Keavney 7,8 and Ioakim Spyridopoulos 1,6*
Cytomegalovirus (CMV) seropositivity in adults has been linked to increased cardiovascular disease burden. Phenotypically, CMV
infection leads to an inflated CD8 T-lymphocyte compartment. We employed a 8-colour flow cytometric protocol to analyse
circulating T cells in 597 octogenarians from the same birth cohort together with NT-proBNP measurements and followed all
participants over 7 years. We found that, independent of CMV serostatus, a high number of CD27−CD28+ CD8 EMRA T-
lymphocytes (TEMRA) protected from all-cause death after adjusting for known risk factors, such as heart failure, frailty or cancer
(Hazard ratio 0.66 for highest vs lowest tertile; confidence interval 0.51–0.86). In addition, CD27−CD28+ CD8 EMRA T-lymphocytes
protected from both, non-cardiovascular (hazard ratio 0.59) and cardiovascular death (hazard ratio 0.65). In aged mice treated with
the senolytic navitoclax, in which we have previously shown a rejuvenated cardiac phenotype, CD8 effector memory cells are
decreased, further indicating that alterations in T cell subpopulations are associated with cardiovascular ageing. Future studies are
required to show whether targeting immunosenescence will lead to enhanced life- or healthspan.
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INTRODUCTION
We have previously shown the impact of cytomegalovirus (CMV)
seropositivity, which reflects chronic latent infection with this
herpes virus, on cardiovascular (CV) mortality in octogenarians.1 So
far, no study has investigated the CMV-related T-cell phenotype in
detail or its association with outcome in such a large population.
Our goal was to assess the impact of CMV-related as well as
unrelated changes to the T-cell phenotype to CV mortality in
octogenarians, using a polychromatic, 8-colour protocol to
accurately assess the T-cell phenotype by flow cytometry2 in
597 octogenarians from the same cohort (Newcastle 85+ study).3,4
In addition, patients were characterized more accurately regarding
(a) pre-existing comorbidity, such as subclinical heart failure
(reflected by increased NT-proBNP plasma levels) or frailty, (b) in-
depth description of circulating T cell phenotypes and (c) 7 years
follow-up data on health and mortality outcomes. We found in this
unique cohort of octogenarians that among peripheral blood
immune cells lymphocytes have the strongest predictive power
for outcome. Among lymphocytes a large amount of cytotoxic
CD8 TEMRA cells as well as their loss of CD28 are independent
predictors of increased mortality. It appears that virus-dependent
as well as -independent changes to the CD8 T cell compartment
are strong determinants of outcome in unselected octogenarians.
RESULTS AND DISCUSSION
Baseline parameters and gender differences
In 597 participants from phase II of the Newcastle 85+ study (86.5
years old, all born in 1921), male participants (38 %) were more
likely to be smokers (67% vs 45%), have CV disease (CVD, 53% vs
43%), and previous myocardial infarction (20% vs 11%) than
female participants (Supplementary Table 1). In contrast, males
were less frail (11% vs 23%) than females. Despite similar CMV-
seropositivity in both groups (84% vs 86%, Supplementary Table 1),
women showed higher lymphocyte counts (1.7 vs 1.55 × 109/μl,
Supplementary Table 2), an increased CD4/CD8 ratio (2.7 vs 2.1), a
higher frequency of naïve CD4 (47.2% vs 37.4%) and finally more
naïve CD8 T-cells (8.5% vs 5.4%, Supplementary Table 3). This was
unrelated to the higher prevalence of CVD (Supplementary
Table 4).
Cytomegalovirus seropositivity drives CD27–CD28− effector
memory phenotype
We defined CD8 TEMRA cells explicitly according to the commonly
used Sallusto classification as CD8 T-lymphocytes lacking the C–C
chemokine receptor type 7 (CCR7) and re-expressing CD45RA,
thus CD3+CD4–CD8+CCR7−CD45RA+.5 The other T-lymphocyte
subsets were classified as naïve (CCR7+CD45RA+), central
memory (CM CCR7+CD45RA–) and effector memory (EM;
CCR7−CD45RA−) cells. Of note, some authors chose a slightly
different, less detailed subclassification for T-cell subsets by
replacing CD45RA with CD27.6 CMV seropositivity in our cohort
did explain (a) a lower CD4/CD8 ratio (2.2 vs 5.0) due to a higher
proportion of CD8 T-cells, (b) reduced CD4 and CD8 naïve cells
and (c) a higher proportion of CD8 TEMRA cells (57% vs 32%,
Supplementary Tables 5 and 6). The most significant difference in
phenotype though was the very large increase in CD27/CD28
double negative subpopulations across all CD4 and CD8 memory
T cell subsets (Supplementary Tables 5 and 6, Supplementary Fig.
1b). CMV-specific T cells are known to increase mainly in elderly
CMV seropositive individuals (above the age of 65), displaying a
CD27−CD28− effector memory phenotype,7 commonly
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considered a hallmark of immunosenescence. This is believed to
contribute to the weakened immune status observed in the
elderly. Accordingly, Derhovanessian et al. demonstrated that
individuals from families enriched for longevity (with 30% lower
mortality risk compared to the general population) are resistant to
CMV-driven, age-associated reduction in naive T cells and
accumulation of CD27−CD28− effector memory T cells.8
NT-proBNP is a strong predictor of outcome in octogenerians
Plasma samples for NT-proBNP measurement were aliquoted on
day of collection and stored at −80 °C. NT-proBNP was measured
by an electrochemiluminescent sandwich immunoassay using the
Modular Analytics E170 system (Roche Diagnostics, Lewes, UK).
The between-batch coefficient of variation was 1.5–3.5% from
122–4322 ng/l, with an analytical range of 5–35000 ng/l. The use
of NT-proBNP measurements makes part of clinical guidelines to
reduce the number of unnecessary echocardiograms, as low levels
of NT-proBNP rule out a diagnosis of heart failure.9 A recently
published multi-centre study, within a combined in-patient and
out-patient setting and a follow-up of 2 years, showed that NT-
proBNP levels at clinical stabilisation are strongly and similarly
related to survival in heart failure regardless of ejection fraction
and that a given level of NT-proBNP portends the same risk of
death in heart failure with preserved (HFpEF) or reduced (HFrEF)
ejection fraction.10 The strong association between NT-proBNP
and outcomes in HF regardless of EF is clinically important. NT-
proBNP reflects LV wall stress, and is therefore expected to be
lower in HFpEF than HFrEF on the basis of LaPlace’s Law. Yet, for a
given level of NT-proBNP, prognosis for HFpEF was as poor as for
HFrEF.10 NT-proBNP measurements thus provide a critical tool for
clinicians to risk stratify their patients with HFpEF, whether in the
stable situation or the acute decompensated state. As shown in
Fig. 1, NT-proBNP plasma levels are a strong predictor of all-cause
mortality in octogenarians (p < 0.001).
Survival and Cox-regression analysis
Independent determinants for all-cause mortality were as
expected: gender, frailty, pre-existing heart failure (reflected by
NT-proBNP) and cancer (Fig. 1). Interestingly, higher mortality in
men vs women (75% vs 63%, p= 0.002) was exclusively related to
increased CV mortality (30.2 vs 21.8%, Supplementary Table 1).
Following adjustment of the Cox-regression analysis for heart
failure (NT-proBNP), cancer and frailty, the only independent
predictors remaining were total lymphocyte count reflecting
thymic function (hazard ratio (HR) and 95% confidence interval
(CI) for highest vs. lowest tertile= 0.70 and 0.53–0.93 respectively),
percentage of CD8 TEMRA cells (HR 1.46; CI 1.12–1.92) as a surrogate
for immunosenescence, and finally expression of the co-receptor
CD28 in CD8 TEMRA cells (HR 0.66; CI 0.51–0.86) (Tables 1 and 2).
Non-cardiovascular mortality was predicted by a low hemoglobin
and TEMRA cells as well as expression of CD28 (Supplementary Table
7). Cardiovascular mortality was predicted by high basophil
number (reflecting inflammation), low levels of plasma TGF-beta
and lack of CD28 expression in the CD27− CD8+ TEMRA cells
(Supplementary Table 7). While the main three subsets of CD8
EMRA T-cells were all age and CMV-dependent, thus all linked to
immunosenescence, CD27−CD28+ CD8+ TEMRA cells were not
(Fig. 2a, b). This sub-population ranged between 0.2% and 20% of
the whole EMRA population (Fig. 2b) and demonstrated high
KLRG1 levels (Fig. 2a, Supplementary Fig. 1C), which is preferen-
tially found on antigen-experienced CD8 memory T-cells (Supple-
mentary Fig. 1A). Virus-specific CD8+ T cells are mostly KLRG1+ in
chronic human viral infections, such as CMV, EBV and HIV, but not
in resolved infection (e.g. influenza virus).11 Verma et al. have also
shown recently that the CD27−CD28+ subset of the heterogenous
CD8 TEMRA population does not express the differentiation marker
CD57, has longer telomeres than the CD28− subsets, and is
capable of high proliferative capacity and differentiation plasti-
city,12 hence the expression of CD28 in CD27− CD8 T cells likely
reflects a subset of non-terminally differentiated effector cells.
Senolytic therapy
CD8+ TEMRA cells have been shown to be functionally senescent,
as demonstrated by both proliferative arrest and the increased
production and secretion of inflammatory mediators characteristic
of a senescence-associated secretory phenotype (SASP).6 In proof
of principle experiments we therefore aimed to investigate
whether it was possible to reduce immunosenescence in aged
mice using a senolytic drug, which we have previously shown
attenuates the age-related cardiac phenotype.13,14 Indicative of
immunosenescence, CD8 effector memory cells were increased
and naïve CD8 T-cells were significantly decreased in aged mice.
This phenotype was rescued by navitoclax (Fig. 2c). While in the
current study we have not investigated the mechanisms by which
senolytics increase the naive T-cell population, clearance of
senescent cells via senolytics promotes hematopoietic stem cell
function15 and in human trials, senolytic treatment attenuates
circulating SASP.16 It is, therefore, possible that as well as
eliminating senescent CD8 cells senolytic treatment influences
the balance of different T-cell subpopulations via changing the
dynamics of lymphocyte proliferation as a result of reduced
systemic inflammation or rejuvenation of progenitor pools.
In conclusion, out of all immune cells, the subset of
CD27− CD28+ CD8+ TEMRA cells appeared to be the strongest
independent predictor of all-cause mortality in the elderly. Most
likely, this subset reflects the size of a TEMRA subcompartment with
retained plasticity and proliferative capacity, among otherwise
senescent effector memory cells. Therefore, they might represent
quickly accessible effector memory cells in the elderly, able to
combat infections. Alternatively, a large pool of CD28+ cells
indicates that less terminally differentiated EMRA cells are
necessary to control chronic latent infections such as CMV, hence
they are indicative of less underlying subclinical inflammation.
Future studies have to show whether targeting immunosenes-
cence and/or increasing immunocompetent immune cells with
senolytics, or by telomerase-activators such as TA-65,17,18 will lead
to enhanced life- or healthspan. Our TACTIC trial (Telomerase
ACTivator to reverse Immunosenescence in Acute Coronary
Syndrome: a double-blind, phase II, Pilot randomized controlled
trial; ISRCTN 16613292) will show whether activation of telomerase
by 12-month treatment with TA-65 in patients over the age of 65
with acute coronary syndrome reduces the percentage of pro-
inflammatory CD8 TEMRA lymphocytes, increases telomere length,
and finally antagonize systemic inflammation and SASP.
METHODS
Study population
The recruitment strategy for the Newcastle 85+ Study has been previously
published.3,4 Briefly, individuals born in 1921 living in Newcastle or North
Tyneside (North-East England) were recruited at around age 85 through their
general practice, including those in institutional accommodation and those
cognitive impaired. The Newcastle 85+ cohort is socio-demographically
representative of the North-East of England as well as the population of
England and Wales.4 The study conformed to the requirements of the
Declaration of Helsinki and received ethical approval from the Newcastle and
North Tyneside 1 Research Ethics Committee (reference number 06/Q0905/
2). We sought written informed consent from participants directly or, when
they lacked such capacity to consent, from a relative or carer.
PBMCs isolation, cell cryopreservation and storage
Peripheral blood mononuclear cells (PBMCs) were obtained after Ficoll
density gradient centrifugation using Ficoll-Hypaque. Following isolation,
PBMCs were carefully resuspended in ice-chilled freezing medium
containing RPMI 1640 with 10% FBS, 1% P/S and 10% DMSO (1ml
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medium per 1 × 106 cells) and aliquoted into cryovials. Cell aliquots were
frozen at −80 °C and stored in a liquid nitrogen tank until use.
Lymphocyte immunophenotyping
Blood samples were analysed by 8-colour flow-cytometry assays, which
were performed similarly as previously described.2 Shortly, frozen PBMC
aliquots were quickly thawed, and washed using an automatic cell washer.
Following primary wash step, cell viability and cell numbers were analyzed
using Vi cell counter. PBMC staining was performed with CD3-QDot605
and CD45RA-PacificBlue (both Invitrogen), CD4-AlexaFluor700, CD8-APC-
H7, CCR7-PE/Cy7, CD27-APC, and CD28-PerCp/Cy5.5 (all BD Biosciences).
Following three wash steps, LIVE/DEAD® Fixable Aqua Dead Cell Stain
(Thermo Fisher Scientific, Waltham, MA, USA) was added to allow
discrimination of viable and dead cells. Samples were measured on a BD
LSR II cytometer using BD FACSDiva acquisition software. At least 100,000
viable cell events per sample were acquired. The gating scheme is
depicted in Fig. 2a.
Fig. 1 Gender, comorbidity and lymphocytes predict survival in the Newcastle 85+ study. Kaplan-Meier curves with their respective log-
rank p-values identify male gender and pre-existing comorbidity, such as cancer, frailty, anaemia or heart failure (reflected by elevated plasma
NT-proBNP) as predictors of adverse outcome in octogenarians. Likewise, low lymphocyte counts (tertiles <1420 × 106/μl, 1420–1940 × 106/μl
and >1940 × 106/μl) and a low percentage of CD27−CD28+ CD8+ TEMRA cells (tertiles <1.9%, 1.9–3.4% and >3.4%) are singular predictors of
reduced survival.
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Animals, procedures and senolytic treatment
C57BL/6 mice were analyzed at either 13 weeks (3 months) or 100 weeks
(23 months) of age. Mice were purchased from Charles River (Charles River
Laboratories International, UK). The project was approved by the Faculty of
Medical Sciences Ethical Review Committee, Newcastle University (project
license no. 60/3864). At ~23 months of age, mice were randomly assigned
to a treatment group. ABT263 (navitoclax) or vehicle alone was
administered to mice by gavage at 50mg/kg body weight per day (mg/
kg/d) for 7 day per cycle for two cycles with a 1-week interval between the
cycles. Mice from each treatment group were then culled by humane
methods and their spleen collected.
Mouse flow-cytometry
Dissected spleens were ground on a pre-wet 70 μm filter with a 2ml
syringe plunger. The filters were washed with 10ml PBS and cell
suspension centrifuged at 300 × g for 5 min at 4 °C. The pellet was
resuspended in 3ml Pharm Lyse red blood cell lysis buffer (BD) and
incubated for 5 min at room temperature. Ten ml Flow-cytometry buffer
(PBS+ 1% BSA+ 0.05% NaN3) was used to stop the reaction, followed by
another centrifugation step. Cell suspension was filtered through a 30 μm
filter and cells were counted using Tali chips (Thermo Fisher Scientific).
Fc receptors of cells were blocked using 1:50 anti-CD16/32 (clone 93,
BioLegend). Around 1 × 106 cells were stained with BV605 anti-CD3
(clone 17A2, BioLegend), BV480 anti-CD4 (clone RM4-5, BD), PerCP-Cy5.5
anti-CD8 (clone 53–6.7, BioLegend), BUV395 anti-CD44 (clone IM7, BD)
and PE anti-CD62L (clone MEL-14, BioLegend). The cells were incubated
for 60 min on ice and washed twice with staining buffer. A 1:10 DAPI
solution was used to distinguish live and dead cells. Flow-cytometry
data were acquired on a BD Fortessa analyser and analysed using FCS
Express (V6, De Novo Software). Please see gating scheme in
Supplementary Fig. 2.
Blood-based biomarkers
Blood samples were collected within 6 months of participant assessment.
Biomarkers were measured from a fasting blood sample that reached the
lab within 1 h for processing. A comprehensive list of the biomarkers
included is in Supplementary Table 2 and the methodological details of the
assays can be found in refs. 1,19,20
Table 1. All cause mortality Cox-regression model: CD8 TEMRA.
N° Individuals N° Events Unadjusted hazard ratio p Adjusted hazard ratioa p
Lymphocytes (×109/l) Tertiles ≤1.42 196 146 1 0.006 1 0.046
1.43–1.93 199 134 0.76 (0.59–0.99) 0.84 (0.64–1.09)
1.94+ 193 117 0.64 (0.49–0.85) 0.70 (0.53–0.93)
Basophils (×109/l) Tertiles ≤0.03 281 183 1 0.162 1 0.134
0.04–0.05 180 126 1.28 (0.99–1.64) 1.30 (1.01–1.67)
0.06+ 127 88 1.13 (0.85–1.51) 1.13 (0.84–1.50)
TGF-beta (ng/ml) Tertiles ≤13.17 188 136 1 0.033 1 0.227
13.18–17.36 190 120 0.72 (0.55–0.94) 0.82 (0.62–1.06)
17.37+ 188 131 0.94 (0.72–1.23) 1.00 (0.76–1.31)
Haemoglobin (g/dl) Tertiles ≤12.30 197 153 1 0.001 1 0.112
12.31–13.60 196 119 0.68 (0.53–0.88) 0.79 (0.61–1.02)
13.61+ 195 125 0.66 (0.51–0.85) 0.79 (0.61–1.03)
CD8 TEMRA (%) Tertiles ≤45.20 186 111 1 0.006 1 0.014
45.21–63.80 186 132 1.36 (1.04–1.77) 1.37 (1.05–1.80)
63.81+ 184 134 1.53 (1.17–1.99) 1.46 (1.12–1.92)
Values are expressed as Mean (Lower, Upper bound of 95% CI)
aAdjusted for Tertiles of NT-proBNP, Cancer and Frailty
Table 2. All cause mortality Cox-regression model: CD8 CD27–CD28+.
N° Individuals N° Events Unadjusted hazard ratio p Adjusted hazard ratioa p
Lymphocytes (x109/l) Tertiles ≤1.42 196 146 1 0.068 1 0.200
1.43–1.93 199 134 0.84 (0.65–1.09) 0.94 (0.72–1.22)
1.94+ 193 117 0.72 (0.55–0.95) 0.78 (0.59–1.03)
Basophils (x109/l) Tertiles ≤0.03 281 183 1 0.138 1 0.099
0.04–0.05 180 126 1.28 (1.00–1.65) 1.32 (1.02–1.70)
0.06+ 127 88 1.18 (0.88–1.57) 1.18 (0.88–1.57)
TGF-beta (ng/ml) Tertiles ≤13.17 188 136 1 0.038 1 0.281
13.18–17.36 190 120 0.72 (0.55–0.94) 0.82 (0.63–1.06)
17.37+ 188 131 0.92 (0.70–1.20) 0.96 (0.74–1.26)
Haemoglobin (g/dl) Tertiles ≤12.30 197 153 1 0.000 1 0.072
12.31–13.60 196 119 0.65 (0.50–0.84) 0.77 (0.59–1.00)
13.61+ 195 125 0.63 (0.49–0.82) 0.77 (0.59–1.01)
CD8 CD27–CD28+ (%) Tertiles ≤1.90 190 140 1 0.013 1 0.004
1.91–3.40 187 122 0.78 (0.60–1.00) 0.72 (0.55–0.93)
3.41+ 179 115 0.68 (0.53–0.89) 0.66 (0.51–0.86)
Values are expressed as Mean (Lower, Upper bound of 95% CI)
aAdjusted for Tertiles of NT-proBNP, Cancer and Frailty
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Morbidity, mortality and causes of death
A multidimensional health assessment was carried out during three visits
in the participant’s usual dwelling by a dedicated research nurse. Data on
pre-existing diseases and prescribed medication were obtained from
reviewing the medical records held for the participants at their respective
general practice. Date and cause of death were obtained through the UK
Health and Social Care Information Service. Survival time (in months) was
calculated from date of blood draw to date of death or censored at 30 April
2015 (median follow-up 61 months, overall survival rate 32.5%). We
defined cardiovascular death as ICD codes I00–I69 and death due to
myocardial infarction or stroke to be I20–I25 and I60–I69.
Statistics
Our total cohort for the study comprised of 597 participants. We compared
by gender the health measurements, socio-demographic and biomarkers
distributions for our participants by Chi-square tests for categorical
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Fig. 2 Loss of naïve CD8 T-cells with increased age in men and mice. a Gating strategy for CD8 TEMRA subsets shows viable cells, singlets and
lymphocyte gates, followed by T-cells (top row), CD8+ T-cells and further classification into naïve, CM, EM and TEMRA CD8+ cells depending on
their CCR7 and CD45RA expression (middle row). The latter are then plotted against CD27 and CD28 co-receptors (middle row), and KLRG1
expression is depicted for each of the four CD27/CD28 subsets (lower row). b Distribution of CD8 TEMRA subsets according to CD27 and CD28
co-receptors (healthy young control group (n= 18) vs. 85+ study population (n= 565). Loss of CD27/CD28 double positive cells with higher
age. c Percentage of T-cell subsets from mouse splenocytes, relative to total CD8 population, in different experimental groups (young n= 6,
old n= 7, and old mice treated with navitoclax n= 8). Data are depicted as single data points and mean (red line). ***p < 0.001; **p < 0.01; *p <
0.05 using 1-way ANOVA.
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variables, with data represented as percentage, or by Mann-Whitney U
tests for ordinal variables, with data represented as median and
interquartile range (IQR) (Supplementary Tables 1 and 2). For each of
those variables we performed a Kaplan-Meyer Survival analysis by
categories or by tertiles (on ordinal variables) with a Log-rank test. The
rational for the selection of covariates included on the final Cox-Regression
Models was as follows:
Forward selection Cox-Regression analysis was performed on tertiles of
NT-proBNP and tertiles of Immunosenescence variables: subpopulations
Naïve, CM, EM and TEMRA for CD4 and CD8, with an alternative model
where CD8 TEMRA were replaced by detailed CD8 TEMRA CD27/
CD28 subpopulations. Those models were performed adjusting for
Gender, Anemia, Cancer, Diabetes, Renal Impairment, Tertiles of
Rockwood Frailty Score and tertiles of Total cholesterol.
Forward selection Cox-Regression analysis was performed on tertiles of
NT-proBNP and tertiles of all remaining blood biomarkers. An
alternative model was run with only those biomarkers with significant
Log-rank Kaplan-Meyer survival analysis. Those models were performed
adjusting, as before, for Gender, Anemia, Cancer, Diabetes, Renal
Impairment, Tertiles of Rockwood Frailty Score and tertiles of Total
cholesterol.
From the outcomes of the above we were able to select the 5 variables
that we carried over to the final analysis:
Lymphocytes, Basophils, TGF-beta, Haemoglobin and either CD8 TEMRA
or CD8 TEMRA CD27−CD28+, with the relevant adjustment for tertiles of
NT-proBNP, Cancer and tertiles of Rockwood Frailty Score. The Cox-
regression analysis were performed on overall Mortality/Survival as well as
discriminating between Cardiovascular Mortality and Non-cardiovascular
mortality. See Flow chart attached (Supplementary Fig. 3).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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